When the pandemic began, more than 1,000 trials were delayed as the focus shifted to minimizing coronavirus exposure and driving COVID-19 vaccine and treatment trials. The impact of these delays on the progress of medical research will likely be felt for years to come, but for now, many sponsor companies are playing catch-up.
In this whitepaper, we examine what that catch-up looks like, specifically with regard to those studies that need to be rescued. We explore the concept of rescue studies, discussing when and why sponsors may need to rescue a trial, what considerations are key, and how to successfully approach a rescue trial. We end with a thorough look at how sponsors can get their trials off to a strong start, and avoid needing a rescue at all.
Download our whitepaper to learn more.